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Summary
Type 2 diabetes is associated with defects in insulin signaling and the resulting abnormal glucose and lipid metabolism. The
complexity of insulin signaling cascades is highlighted by the existence of multiple isoforms of target proteins implicated
in metabolic and gene-regulatory events. We utilized siRNA to decipher the specific role of predominant insulin receptor
substrates and Akt isoforms expressed in human skeletal muscle. Gene silencing revealed specialized roles of insulin sig-
naling cascades tometabolic endpoints. IRS-1 and Akt2 were required for myoblast differentiation and glucosemetabolism,
whereas IRS-2 and Akt1 were dispensable. A key role of IRS-2 and Akt1 in lipid metabolismwas revealed, highlighting recip-
rocal relationships betweenmetabolic pathways. Unraveling the isoform-specific regulation of glucose and lipidmetabolism
by key elements along insulin signaling cascades through siRNA-mediated gene silencing in human tissues will facilitate the
discovery of novel targets for the treatment of diabetes and related metabolic disorders.Introduction
Insulin mediates multiple metabolic responses in skeletal mus-
cle, including glucose and fatty-acid uptake and metabolism,
as well as gene-regulatory responses. Insulin receptor activa-
tion results in phosphorylation of insulin receptor substrates
(IRSs), which in turn relay positive and negative signals along
complex networks of intracellular circuitry that is only beginning
to be unraveled. Type 2 diabetes mellitus is associated with de-
fects in insulin signaling in skeletal muscle, and this is correlated
with impaired whole-body glucose homeostasis (Bjo¨rnholm
et al., 1997; Krook et al., 2000). Thus, a molecular resolution of
the pathways controlling glucose homeostasis may identify tar-
get genes responsible for the insulin resistance observed in
diabetic patients. Insulin-mediated activation of IRS, phosphati-
dylinositol 3-kinase (PI3K), and Akt has been implicated in glu-
cose and lipid metabolism; however, the complexity of these
pathways is magnified by the expression of multiple isoforms
of these signal transducers. Evidence from IRS or Akt knockout
models in rodents suggests that insulin action is governed by
isoform- and tissue-specific responses in various metabolic
pathways; however, such knowledge is currently lacking in
human tissues.
Of the six different IRS molecules identified (Holgado-
Madruga et al., 1996; Lavan et al., 1997a, 1997b; Sun et al.,
1991, 1995; Yamanashi et al., 1997), IRS-1 and IRS-2 are
the major substrates participating in insulin action in skeletal
muscle. Defects in IRS-1 or IRS-2 tyrosine phosphorylation
characterize insulin resistance associated with type 2 diabetes
in rodents and humans (Araki et al., 1994; Bjo¨rnholm et al.,
2002; Bouzakri et al., 2003; Krook et al., 2000; Withers et al.,CELL METABOLISM 4, 89–96, JULY 2006 ª2006 ELSEVIER INC. DOI1998; Zierath et al., 2000). Although IRS-1 and IRS-2 share
a high degree of homology (Sun et al., 1995), structural and func-
tional differences exist. Tissue-specific roles of IRS-1 and IRS-2
have been demonstrated in vivo using mouse models with tar-
geted gene deletion (Araki et al., 1994; Withers et al., 1998), or
in vitro using siRNA. IRS-1 mediates insulin-stimulated glucose
metabolism in mouse liver (Taniguchi et al., 2005) and L6 muscle
cells (Huang et al., 2005), whereas IRS-2 controls mitogen-acti-
vated protein kinase (MAPK, Erk 1/2) (Huang et al., 2005) and
lipid metabolism (Taniguchi et al., 2005). In contrast to mice, hu-
mans do not express a functional IRS-3 ortholog gene, and thus
an additional level of compensation in the insulin signaling path-
way appears to be lost (Bjo¨rnholm et al., 2002). Therefore, the
specific roles of IRS isoforms on insulin action in human skeletal
muscle are incompletely resolved.
Three highly homologous isoforms of Akt (Akt1–3) are ex-
pressed in mammalian cells. Akt1 is the most ubiquitously ex-
pressed isoform shown to be involved in growth (Cho et al.,
2001b). Akt2 is also expressed in most tissues at comparably
lower levels than Akt1, except in insulin-responsive tissues,
where expression is higher (Altomare et al., 1998). Studies using
knockout mice reveal that Akt2 is indispensable for glucose ho-
meostasis (Cho et al., 2001a), and cellular studies using siRNA
underscore the importance for this isoform for glucose uptake
in skeletal muscles (Huang et al., 2005). Akt3 is expressed in tes-
tes and brain (Brodbeck et al., 1999) and is essential for growth
but not glucose homeostasis (Easton et al., 2005). Other tissues,
including human skeletal muscle, show low or undetectable
Akt3 expression (Bouzakri et al., 2004). siRNA against Akt1 or
Akt2 in 3T3-L1 adipocytes highlights a primary role of Akt2 in in-
sulin signaling to glucose transport and GSK-3, with redundancy10.1016/j.cmet.2006.04.008 89
S H O R T A R T I C L EFigure 1. Silencing of IRS-1, IRS-2, Akt1, and Akt2 in myoblasts or myotubes
A) Morphological changes of human skeletal muscle after silencing of IRS-1 and Akt2 in myoblastes.
B) Representative immunoblot showing protein expression of IRS-1, IRS-2 Akt1, Akt2, or desmin after silencing of the respective targets in myotubes. Graph shows
mean 6 SEM presented as arbitrary units relative to control cells incubated under basal conditions. *p < 0.05 versus untranfected cells.of Akt1 and Akt2 isoforms noted along these pathways (Jiang
et al., 2003). The Akt isoform-specific effects along pathways
that regulate lipid metabolism are unknown.
We used siRNA-mediated gene silencing to specifically sup-
press IRS-1, IRS-2, Akt1, or Akt2 expression in primary human
skeletal muscle cells to determine whether there are specific
or redundant roles of these targets on insulin-mediated signal
transduction, including phosphorylation of Erk1/2, the Akt sub-
strates AS160, and forkhead protein FoxO1/FoxO4, as well as
glucose and lipid metabolism. Our results provide evidence for
specialized roles of insulin signaling cascades to metabolic end-
points as demonstrated by the differential roles of IRS-1/Akt2
in controlling glucose metabolism and IRS-2/Akt1 in controlling
lipid metabolism.
Results and discussion
Silencing of IRS-1, IRS-2, Akt1, and Akt2 in myoblasts
and myotubes
The effect of siRNA to suppress IRS-1, IRS-2, Akt1, or Akt2
mRNA and protein expression was initially validated in myoblast90(undifferentiated) cultures. siRNA was transfected into 80%
confluent cells and differentiation was induced the next day.
For each gene, two independent siRNA sequences were vali-
dated for effects to silence target gene expression (sequences
available on request). All constructs decreased protein expres-
sion of the specific targeted gene. Striking morphological
changes were also noted in myoblasts depleted of either IRS-1
or Akt2 (Figure 1A). Silencing of either IRS-1 or Akt2 in myoblasts
inhibited subsequent survival and differentiation into myotubes.
In contrast, growth and cell survival were unaltered in myoblasts
depleted of either IRS-2 or Akt1. These results suggest in hu-
mans that the IRS-1/Akt2 signaling network is indispensable
for myoblast differentiation. This result is consistent with knock-
out mice, whereby both IRS-1 and IRS-2 play a critical role for
embryonic and postnatal growth, with IRS-1 playing a predomi-
nant role (Withers et al., 1998). However, our results contrast Akt
isoform knockout mice, in which Akt1, rather than Akt2, plays an
important role in organismal growth (Cho et al., 2001b).
Due to the profound change in cell growth and differentiation,
the effect of IRS and Akt ablation on insulin signaling and metab-
olism was determined in myotubes. Differentiated myotubesCELL METABOLISM : JULY 2006
IRS/Akt signaling in human skeletal musclewere transfected with siRNA against the target genes 2 days af-
ter the induction of the myotube differentiation program. Silenc-
ing of IRS-1, IRS-2, Akt1, or Akt2 in myotubes was associated
with a profound reduction in protein expression of each respec-
tive target gene (Figure 1B), without effect on either cell mor-
phology or subsequent differentiation after 4 days. Double
transfection of cells with IRS-1 and IRS-2 or Akt1 and Akt2 in
order to achieve a dual knockdown of both isoforms of each
gene also decreased protein expression of the target genes
(Figure 1B). Gene silencing did not alter myotube morphology
(data not shown) or protein expression of the myogenic marker
desmin (Figure 1B). Thus, all subsequent metabolic parameters
were determined in myotubes transfected with siRNA to circum-
vent the confounding effect of gene silencing of each target on
differentiation, as observed in the transfected myoblasts.
Insulin signal transduction
To further delineate signaling specificity in human skeletal mus-
cle, we determined phosphorylation of Akt, AS160, and FoxO1/
FoxO4 in differentiated myotubes. AS160 is the most proximal
Akt substrate identified to date in the insulin signaling cascade
to GLUT4 translocation (Kane et al., 2002; Sano et al., 2003;
Zeigerer et al., 2004) and plays a role in mediating the metabolic
effects of insulin on glucose uptake. Akt also phosphorylates and
inactivates members of the FoxO family of transcription factors
(Accili and Arden, 2004), directly linking Akt to gene-regulatory
events. In the phosphorylated form, FoxO is tethered in the cy-
toplasm, and activation by dephosphorylation permits nuclear
translocation and activation of responsive genes.
Silencing of either IRS-1 or Akt2 abolished insulin-mediated
phosphorylation of Akt at Ser473, AS160, and FoxO1/FoxO4
and partly (50%) decreased Akt Thr308 phosphorylation (Fig-
ure 2). Conversely, suppression of either IRS-2 or Akt1 was with-
out effect on phosphorylation of Akt at Ser473, AS160, and
FoxO1/FoxO4 and dramatically decreased Akt Thr308 phos-
phorylation (Figure 2). Protein expression of Akt, AS160, and
FoxO1/FoxO4 was unaltered after IRS-1 and/or IRS-2 silencing
(data not shown).The coupling between IRS-1 and Akt Ser473
phosphorylation corresponds with similar observations in L6
muscle cells, whereby IRS-1 was silenced using siRNA (Huang
et al., 2005). Interestingly in human muscle cells, Akt Thr308
phosphorylation was mainly dependant on IRS-2 and Akt1 ex-
pression. Furthermore, insulin-mediated Akt Thr308 phosphory-
lation was lower in cells depleted of either IRS-2 or Akt1 versus
cells depleted of either IRS-1 or Akt2, such that knockdown of
either IRS-1 and IRS-2 or Akt1 and Akt2, insulin action on phos-
phorylation of Akt at Ser473 and Thr308, AS160, and FoxO1/
FoxO4 was completely abrogated. Thus, IRS-1 and Akt2 medi-
ate phosphorylation of Akt Ser473 and AS160 in response to
insulin, whereas IRS-2 and Akt1 are indispensable. Moreover,
insulin action on FoxO1/FoxO4 phosphorylation was dependent
on IRS-1 and Akt2. This link between IRS-1 and Akt2 partly ex-
plains the effects of gene silencing of these targets on myotube
formation. In differentiating muscle cells, transient inhibition of
FoxO by phosphorylation coordinates exit from the cell cycle
with activation of the terminal differentiation program (Sandri
et al., 2004; Stitt et al., 2004). Thus, silencing either IRS-1 or
Akt2 before the induction of the differentiation process impairs
myotube differentiation. Collectively, this targeted approach to
silence components of insulin signaling cascades reveals that
IRS-1/Akt2 constitutes the main mechanism promoting phos-CELL METABOLISM : JULY 2006phorylation of Akt at Ser473, AS160, and FoxO, whereas Akt
Thr308 phosphorylation is regulated through IRS-1/Akt2 and
IRS-2/Akt1.
We also provide evidence that insulin action on ERK 1/2
MAPK phosphorylation is IRS-2 dependent in human skeletal
muscle (Figure 2), consistent with previous work in L6 muscle
cells showing that IRS-2 selectively contributes to ERK MAPK
signaling (Huang et al., 2005). In contrast, silencing of IRS-1 or
either Akt isoform did not alter basal or insulin action on ERK
1/2 phosphorylation. Thus, ERK 1/2 phosphorylation is down-
stream of IRS-2 and independent of Akt. A possible explanation
for this finding could be that IRS-2 may have a more predomi-
nant role over IRS-1 in mediating gene-regulatory events in skel-
etal muscle. Indeed in human pancreatic cancer cells, increased
IRS-2 expression and elevated ERK MAPK phosphorylation is
linked to excessive growth stimulation of the malignancy
(Schuppin et al., 1998; Kornmann et al., 1998). Alternatively,
the link between IRS-2 and ERK signaling may be of importance
for intracellular metabolic regulation. Thus we next determined
the effects of IRS or Akt isoforms on glucose and lipid metabo-
lism in cultured human myotubes.
Glucose uptake and metabolism
The effect of siRNA silencing of IRS-1, IRS-2, Akt1, or Akt2 was
determined on glucose uptake and glycogen synthesis in differ-
entiated myotubes (Figures 3A and 3B). Four days after trans-
fection, glucose uptake and glycogen synthesis was assessed
under basal conditions and after exposure to 120 nM insulin.
In control cells (untransfected cells or cultured cells transfected
with a scrambled siRNA construct), insulin increased glucose
uptake 2-fold (Figure 3A). Insulin action on glucose uptake
was prevented in myotubes depleted of either IRS-1 or Akt2
and preserved in myotubes depleted of either IRS-2 or Akt1
(Figure 3A). Basal glucose uptake was suppressed in cells in
which either IRS-2 or Akt1 was depleted, although the effect
of insulin was retained. By contrast, basal glucose uptake was
not reduced upon depletion of IRS-1 and Akt2, whereas insulin
stimulation was completely lost. Dual knockdown of either IRS-1
and IRS-2 or Akt1 and Akt2 reduced basal and insulin-mediated
glucose uptake (Figure 3A).
We next determined IRS and Akt isoform specificity on the
rate of glycogen synthesis as estimated by the incorporation
of glucose to glycogen. Insulin increased glycogen synthesis
2- to 3-fold in untransfected cells or cells transfected with a
scrambled siRNA construct (Figure 3B). siRNA-mediated silenc-
ing of either IRS-1 or Akt2 inhibited insulin action on glycogen
synthesis (p < 0.001), whereas silencing of either IRS-2 or Akt1
was without affect. Nevertheless silencing of IRS-2 or Akt1, as
well as dual knockdown of either IRS-1 and IRS-2 or Akt1 and
Akt2, decreased basal glycogen synthesis. Importantly, the ef-
fects of siRNA on IRS and Akt isoforms on glucose incorporation
to glycogen parallel the results obtained for glucose transport.
Silencing of either IRS-1 or Akt2 protein expression, without
any compensatory changes in IRS-2 or Akt1, abolished insulin
action on glucose uptake and glycogen synthesis.
Our observation supporting a role for IRS-1/Akt2 in the regu-
lation of glucose uptake and metabolism is consistent with prior
results, including silencing of IRS isoforms in L6 muscle cells
(Huang et al., 2005) and the characteristics of skeletal muscle
from IRS-1, IRS-2, or Akt2 knockout mice (Cho et al., 2001a;
Higaki et al., 1999; Yamanashi et al., 1997). We also show silencing91
S H O R T A R T I C L EFigure 2. Insulin action on signal transduction
Representative immunoblot highlighting the role of IRS-1, IRS-2, Akt1, or Akt2 on phosphorylation of (A) Akt Ser473, (B) Akt Thr308 (C) AS160, (D) FoxO1/FoxO4, and (E)
ERK1/2 MAPK under basal (open box) or insulin (closed box) treatment. Graph shows mean6 SEM arbitrary units relative to control cells under basal conditions. *p < 0.05
versus untransfected cells at basal, #p < 0.05 versus untransfected cells after insulin stimulation.of either IRS-2 or Akt1 altered basal, rather than insulin-stimu-
lated glucose uptake and glycogen synthesis. Thus, a pathway
involving IRS-1 and Akt2 governs insulin signal transduction on
glucose uptake and metabolism in human skeletal muscle, while
IRS-2 and Akt1 govern basal responses on these parameters.
These results provide molecular evidence to suggest that re-
duced insulin action on glucose transport and metabolism in
skeletal muscle from Type 2 diabetic patients or insulin resistant
obese subjects are linked to impairments in IRS-1 (Bjo¨rnholm
et al., 1997; Krook et al., 2000) and Akt2 (Brozinick et al.,
2003; Gosmanov et al., 2004) signaling.
Palmitate uptake and b oxidation
Elevated free fatty-acid levels are known to compete with glu-
cose for uptake and metabolism (Randle et al., 1963) and inhibit
insulin signal transduction (Griffin et al., 1999). Here we show92that lipid uptake and metabolism is also regulated by path-
way-specific signaling mechanisms. We found that specific de-
letion of IRS or Akt isoforms had divergent metabolic responses
between glucose and lipid metabolism. Indeed, lipid metabo-
lism was also regulated by signal transduction in an IRS or Akt
isoform-specific manner. In control and scrambled siRNA-trans-
fected cells, insulin increased palmitate uptake and decreased
b oxidation (Figures 3C and 3D). Suppression of either IRS-2
or Akt1 increased basal palmitate uptake (Figure 3C), whereas
depletion of either IRS-1 or Akt2 was without effect. Insulin
action on palmitate uptake was unaltered by silencing of IRS-1
or Akt1, ablated by silencing of IRS-2, and increased by silenc-
ing of Akt2. Lipid oxidation was also regulated by signal trans-
duction pathways. Basal b oxidation was decreased in cells de-
pleted of either IRS-1 or Akt2 and increased in cells depleted of
Akt1 (Figure 3D). Insulin action on b oxidation was preserved inCELL METABOLISM : JULY 2006
IRS/Akt signaling in human skeletal muscleFigure 3. Glucose uptake, glycogen synthesis, pal-
mitate uptake, and oxidation
Glucose uptake (A) was measured on differentiated
primary human skeletal muscle myotubes under
basal conditions (open box) and after insulin stimula-
tion (closed box). Measurements were performed af-
ter silencing of IRS-1, IRS-2, Akt1, or Akt2. Glycogen
synthesis (B) was assessed under basal (open box)
and insulin (closed box) treatment after silencing of
the target genes. Glucose uptake and glycogen syn-
thesis are reported as cpm/mg protein/min 6 SEM.
Effect of IRS-1, IRS-2, Akt1, and Akt2 on palmitate
(C) uptake and (D) oxidation under basal (open box)
or insulin (closed box) treatment in differentiated pri-
mary human skeletal muscle myotubes. Palmitate
uptake and oxidation are reported as pmol/mg pro-
tein/min. Data is mean 6 SEM. *p < 0.05 versus un-
transfected cells at basal, #p < 0.05 versus untrans-
fected cells after insulin stimulation.IRS-1-, Akt1-, or Akt2-depleted myotubes and abolished in IRS-
2-depleted cells. A similar role for IRS-2 in lipid metabolism has
been observed in isolated brown adipocytes from IRS-1 or IRS-2
knockout mice studied in culture (Tseng et al., 2005).
Since fatty-acid uptake is partly mediated via ERK1/2 activa-
tion in skeletal muscle (Turcotte et al., 2005), the absence of
insulin-stimulated ERK1/2 phosphorylation in siIRS-2-depleted
myotubes offers an explanation for the lack of insulin action on
palmitate uptake. Moreover, IRS-2 specifically regulates lipid
homeostasis in liver by regulating lipogenic enzyme expression,
as observed in vivo using an adenovirus-mediated RNA interfer-
ence technique to silence IRS-1 and IRS-2 in mice (Taniguchi
et al., 2005). Similar to our results in human skeletal muscle,
IRS isoforms also have complementary roles in the control of
hepatic metabolism, with IRS-1 more closely linked to glucoseCELL METABOLISM : JULY 2006homeostasis and IRS-2 more closely linked to lipid metabolism
(Taniguchi et al., 2005). Dual knockdown of IRS-1 and IRS-2
increased basal palmitate uptake (Figure 3C) and decreased
b oxidation (Figure 3D) and prevented insulin responsiveness
on these parameters. Dual knockdown of Akt1 and Akt2 expres-
sion increased basal b oxidation and palmitate uptake, while the
insulin-stimulated response for b oxidation was preserved but
higher for palmitate uptake (Figures 3C and 3D). Thus for b oxi-
dation and fatty-acid uptake, IRS-2 is necessary for insulin
action, whereas Akt1 is dispensable.
The mechanism for selectivity between specific IRS and Akt
isoforms in human skeletal muscle remains to be established.
However, an emerging concept considers that the complexity
of signaling networks and the integrated control of diverse cellu-
lar responses in insulin-sensitive tissues is under the control of93
S H O R T A R T I C L EFigure 4. Schematic view of signaling pathways
regulating myotube formation and glucose/lipid
metabolismessential mediators or ‘‘critical nodes’’ (Taniguchi et al., 2006).
With this concept, isoform-specific functions at the level of
IRS, PI3K, and Akt provide a framework for the diverse metabolic
and gene-regulatory responses, thereby introducing specificity
into the insulin signaling pathway (Taniguchi et al., 2006). Thus
the PI3K module offers another level of complexity to the insulin
signal transduction cascade. Three distinct classes of PI3K have
been identified in mammals and are classified by substrate spec-
ificity and mode of activation (Shepherd, 2005). Human skeletal
muscle expresses several splice variants of the class I p85a pro-
tein (Lefai et al., 2001; Tsuchida et al., 2002) and at least seven
PI3K adaptor subunit isoforms are differentially regulated by in-
sulin (Shepherd et al., 1997). Whether IRS-1 or IRS-2 displays
a preferential association with the different PI3K isoforms has
yet to be determined, but presumably this identifies a mechanism
by which insulin could utilize specific PI3K adaptor subunit iso-
forms to regulate particular downstream responses and thus in-
troduce specificity into the IRS/PI3K signaling system to Akt. Ad-
ditionally, intracellular compartmentalization of specific isoforms
could also offer an explanation for the mechanism by which Akt1
and Akt2 are differentially coupled to IRS-1 and IRS-2, although
this theory has to date been challenging to assess. Future stud-
ies combining siRNA against PI3K isoforms may reveal the
mechanism for specific IRS coupling to Akt.
The traditional view of insulin signaling is that one pathway
regulates all metabolic and gene-regulatory endpoints. How-
ever, emerging evidence highlights a complex interaction be-
tween distinct signaling modules to orchestrate divergent down-
stream responses (Taniguchi et al., 2006; Biddinger and Kahn,
2005; Ishiki and Klip, 2005; Whiteman et al., 2002). Targeted re-
duction of specific proteins in the insulin signaling cascade us-
ing siRNA facilitates efforts to validate the role of key molecules
regulating skeletal muscle growth and differentiation. However,
the application of siRNA technology to human biology has been
limited by the availability of well-validated cultured cells of hu-
man origin. The identification and characterization of genes in-
volved in the development of metabolic disease using tissues
of human origin offers an advantage over similar work in rodent
models because results can be directly applicable to human
isoforms of the target genes, thereby offering less mystery in
the translating target validation efforts to treatment strategies.94In summary, siRNA-mediated gene silencing reveals specific-
ity in insulin signaling responses governing myotube formation
and glucose/lipid metabolism (Figure 4). Insulin signaling path-
ways involving IRS-1 and Akt2 are required for myotube forma-
tion, phosphorylation of Akt and AS160, and glucose uptake.
Conversely, insulin signaling pathways involving IRS-2 are nec-
essary for lipid uptake and metabolism. Unraveling the isoform-
specific regulation of glucose and lipid metabolism through
siRNA in tissues of human origin will aid in target discovery
efforts to develop diabetes prevention and treatment strategies
to specifically enhance glucose or lipid metabolism.
Experimental procedures
Antibodies and reagent
Phosphospecific antibodies against Akt (Ser473), Akt (Thr308), and ERK1/2
(p42/44 MAPK) kinase (Thr202 and Tyr204) were purchased from New
England Biolabs (Beverly, Massachusetts). Anti-phospho-(Ser/Thr), Akt sub-
strate (PAS), anti-phospho-(Ser256, Ser193) FoxO1/FoxO4 antibody were
obtained from Cell Signaling Technology. The anti-desmin antibody was
from Chemicon (Temecula, California). Radiochemicals, 2-[G-3H]deoxy-
D-glucose (6.0 Ci mmol21 $ l21), and D-[U-14C]glucose (310 mCi $ mmol21 $ l21)
were from Amersham (Uppsala, Sweden). siRNA primers were from Ambion
(Austin, Texas) and Dharmacon (Chicago, Illinois).
Subject characteristics
Skeletal muscle biopsies (rectus abdominus) were obtained with the in-
formed consent of the donors during scheduled abdominal surgery. Subjects
(two male and three female) had no known metabolic disorders. Mean age
was 546 4 years (body mass index of 25.76 1.4 kg3m22 and fasting blood
glucose of 5.26 0.3 mM). The Ethical Committee at the Karolinska Institutet
approved the study protocols.
Cell culture
The satellite cells were isolated from the muscle biopsies by trypsin digestion
and were grown to confluent myoblasts and differentiated into myotubes as
described (Bouzakri et al., 2003).
siRNA design
Two constructs of siRNA oligos for each gene (IRS-1, IRS-2, Akt1, and Akt2)
were designed with 30-overhanging thymidine dimers, following described
procedures (Elbashir et al., 2001). Target sequences were aligned to the hu-
man genome database in a BLAST search to eliminate sequences with
significant homology to other genes.CELL METABOLISM : JULY 2006
IRS/Akt signaling in human skeletal musclesiRNA transfection in myoblasts
Human skeletal muscle cells were seeded in six well plates at 2–33 104 cells/
cm2. At 70%–80% confluence, myoblasts were transfected as described
(Al-Khalili et al., 2003).
siRNA transfection in myotubes
Myotubes were transfected using Lipofectamine 2000 (Invitrogen, Sweden).
Differentiation media were changed to antibiotic-free growth media on day 2
of myotube differentiation. On day 3, individual siRNAs (1 mg/ml) were trans-
fected using lipofectamine in serum-free DMEM (incubating time >16 hr). My-
otubes were then washed with PBS and 2 ml of DMEM containing 2% of FBS
was added in each well. On day 6, cells were deprived of serum for 16 hr be-
fore insulin stimulation. Control cultures were similarly prepared, but without
addition of siRNA (control), or transfected using a scramble primer (siRNA
Scr). The scrambled constructs were similar to the target sequence (same
GC content) encoding a nonspecific siRNA without mammalian homology.
Different scrambled constructs were tested for each experiment to assure
the silencing specificity.
Western blot analysis
Aliquots of cell lysate (20 mg of protein) were resuspended in Laemmli sample
buffer. Proteins were then separated by SDS-PAGE, transferred to PVDF
membranes (Millipore, Massachusetts), blocked with 7.5% nonfat milk,
washed with TBST (10 mM Tris HCl, 100 mM NaCl, 0.02% Tween 20), and
incubated with appropriate primary antibodies overnight at 4ºC. Membranes
were washed with TBST and incubated with an appropriate secondary anti-
body. Proteins were visualized by enhanced chemiluminescence and quan-
tified by densitometry.
Glycogen synthase activity
Glycogen synthase activity was measured as described (Gaster et al., 2001).
Myotubes in six-well dishes were stimulated with or without insulin for 90 min
at 37ºC and incubated with 5 mM glucose DMEM, supplemented with D-
[U-14C] glucose (1 mCi/ml; final specific activity, 0.18 mCi/mmol) for 90 min.
Each experiment was performed in triplicate.
2-deoxyglucose transport
Glucose uptake was performed as described for primary human muscle cells
(Bouzakri et al., 2004).
Determination of free fatty-acid uptake and oxidation by 14CO2
trapping
The free fatty-acid oxidation method (Petersen et al., 2005) was adapted
as described below. Cells were cultured in 25 cm2 flasks. Myotubes were
treated for 120 min with 0.4 mCi of [1-14C] palmitate in 2 ml serum-free
DMEM with or without insulin (120 nM) at 37ºC, in 5% CO2-95% O2. There-
after, 300 ml of 70% perchloric acid was injected through to the medium.
Flasks were laid down with slight agitation for 1 hr at room temperature.
The filter-compass was removed to a scintillation tube and 200 ml of ice-
cold methanol was added. The trapped 14CO2 in the filter was counted in a liq-
uid scintillation counter. To measure the free fatty-acid uptake after CO2 trap-
ping, the flasks were washed five times with TBS-Tween (0.02%) and cells
were lysed with 2 ml of 0.03% SDS for 2 hr at room temperature with slight
agitation. Lysates (400 ml) were transferred to 4 ml scintillation fluid and the
amount of [1-14C] in the lysate was counted in a liquid scintillation counter.
Protein content of each sample was determined by the BioRad method.
Results reported as cpm/mg of protein.
Statistics
Data are presented as mean 6 SEM. Differences between groups were de-
termined using two-way ANOVA. Fisher’s least significant difference post-
hoc analysis was used to identify significant differences.
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